1
|
AB1586-PARE MULTI-CENTER, RANDOMIZED, OPEN-LABEL, 2-ARM PARALLEL STUDY TO COMPARE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AVT02 ADMINISTERED SUBCUTANEOUSLY VIA PREFILLED SYRINGE OR AUTOINJECTOR IN HEALTHY ADULT VOLUNTEERS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4763] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundAVT02 is an investigational biosimilar to adalimumab. It is approved in Europe, Canada, and the UK. It is not approved by the US Food and Drug Administration (FDA).ObjectivesTo evaluate the pharmacokinetic similarity of 100 mg/mL AVT02, an investigational biosimilar of adalimumab, when administered either via a pre-filled syringe, or with a newly developed autoinjector in healthy adult subjects.MethodsThis was a Phase 1, randomized, open-label, parallel-group study in which 207 healthy adult subjects were randomized in a 1:1 ratio to receive 100 mg/mL AVT02 either via a pre-filled syringe, or with an autoinjector, stratified by body weight. Subjects received a single subcutaneous 40 mg dose on Day 1. Pharmacokinetics, immunogenicity, local injection site reactions, and adverse events were assessed prior to, and up to 64 days after, study drug administration.ResultsThe results observed supported the assessment of pharmacokinetic similarity of investigational AVT02 administered by pre-filled syringe or with an autoinjector. The 90% CIs for the ratios of geometric least square means for the primary pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ were contained within prespecified margins 80% and 125%, based on an analysis of variance model with treatment as a fixed effect. The mean serum concentration-time profile of adalimumab by treatment group is shown in Figure 1.Figure 1.Mean Serum Concentration-Time Profile of Adalimumab by Treatment Group on Semilogarithmic Scale (Pharmacokinetic Population)Binding anti-drug antibodies were detectable at the end of study visit on Day 64 in 100% and 97.0% of subjects in the pre-filled syringe administration and the autoinjector groups, respectively. Of those subjects positive for anti-drug antibodies, 85.7% and 86.5% further tested positive for neutralizing antibodies in the pre-filled syringe administration and autoinjector groups, respectively. The frequency of local administration site reactions was 11.8% overall and similar between treatment groups. The most frequently reported treatment-emergent adverse events in both treatment groups were under the SOC: Infections and infestations (56.0% in the AVT02-pre-filled syringe group and 45.2% in the AVT02-autoinjector group). The safety profiles were generally similar between treatment groups.ConclusionThe results observed supported the assessment of pharmacokinetic similarity between the pre-filled syringe and autoinjector delivery systems after a single subcutaneous 40 mg dose. The autoinjector delivery system was generally well tolerated in healthy subjects, with a safety and immunogenicity profile similar to that observed with 100 mg/mL AVT02 administered using a pre-filled syringe.ClinicalTrials.gov Identifier: NCT03983876Disclosure of InterestsChristopher Wynne: None declared, Heimo Stroissnig Employee of: Alvotech, Roshan Dias Employee of: Alvotech, Joanna Sobierska Employee of: Alvotech, Eric Guenzi Employee of: Alvotech, Hendrik Otto Employee of: Alvotech, Abid Sattar Employee of: Alvotech, Halimu N. Haliduola Employee of: Alvotech, Elin Edwald Employee of: Alvotech, Fausto Berti Employee of: Alvotech
Collapse
|
2
|
AB0195 PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF A PROPOSED BIOSIMILAR MSB11456 VERSUS BOTH THE US-LICENSED AND EU-APPROVED TOCILIZUMAB: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, SINGLE-DOSE TRIAL IN HEALTHY ADULTS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.74] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Tocilizumab, a biologic disease-modifying antirheumatic drug, is a recombinant humanized monoclonal immunoglobulin G1 antibody against the interleukin-6 receptor (IL-6R). MSB11456 is a proposed biosimilar to the US-licensed tocilizumab and EU-approved tocilizumab. Prior to initiation of its clinical development program, MSB11456 was considered highly similar to the reference products based on extensive in vitro pharmacological testing and functional activity assays.Objectives:This double-blind, parallel-group phase I study (NCT03282851) assessed the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of MSB11456 to US-licensed and EU-approved tocilizumab and provided data on the similarity of safety profiles and immunogenicity of MSB11456 and the reference products in healthy adult subjects.Methods:Healthy adult volunteers were randomized to receive a single 162 mg subcutaneous injection of MSB11456, US-licensed tocilizumab, or EU-approved tocilizumab. Samples for PK/PD and immunogenicity analysis were taken predose, up to 29 days postdose, and at the end of study visit (day 48). Primary endpoint PK parameters were natural log transformed and analyzed using analysis of covariance (ANCOVA) methods; results were then transformed back to the original scale. Secondary PD analysis measured serum soluble IL-6R and serum C reactive protein (sCRP) parameters, and data were analyzed using a method similar to that for PK data. Safety data were collected throughout the study and analyzed descriptively.Results:685 subjects were randomized and treated. Results of the primary PK analysis demonstrated bioequivalence between MSB11456 and both US-licensed and EU-approved tocilizumab, as well as between the reference products, since all corresponding 90% confidence intervals (CIs) for the geometric least squares mean (LSM) ratios were within the predefined 80.00% to 125.00% equivalence margin (Table 1). PD analyses also demonstrated equivalence of MSB11456 and both US-licensed and EU-approved tocilizumab, as well as between the reference products. Safety, tolerability and immunogenicity were also comparable between treatments. The incidence of tocilizumab-specific neutralizing antibodies was low (<3% for all three products).Conclusion:PK and PD equivalence of MSB11456, US-licensed tocilizumab, and EU-approved tocilizumab were demonstrated with comparable immunogenicity, safety, and tolerability for the three products. This study adds to the totality of evidence in support of MSB11456 as a proposed biosimilar to tocilizumab.Table 1.Results of primary PK analysisParameterTreatmentnRatio of geometric LSMs (%)90% CI of ratioMSB11456 vs US-licensed tocilizumabAUC0–∞MSB11456194106.1696.80, 116.43US-licensed tocilizumab190AUC0–tMSB11456230104.1593.58, 115.90US-licensed tocilizumab226CmaxMSB11456230104.4595.05, 114.77US-licensed tocilizumab226MSB11456 vs EU-tocilizumabAUC0–∞MSB11456194104.0394.96, 113.96EU-approved tocilizumab200AUC0–tMSB1145623094.7885.15, 105.50EU-approved tocilizumab224CmaxMSB1145623094.8386.28, 104.22EU-approved tocilizumab224US-licensed vs EU-approved tocilizumabAUC0–∞US-licensed tocilizumab19097.9989.40, 107.41EU-approved tocilizumab200AUC0–tUS-licensed tocilizumab22691.0181.71, 101.36EU-approved tocilizumab224CmaxUS-licensed tocilizumab22690.7982.57, 99.84EU-approved tocilizumab224AUC, area under the serum concentration-time curve (µg·h/mL); AUC0–∞, AUC from time zero to infinity; AUC0–t, AUC from time zero to the time of the last quantifiable concentration; Cmax, maximum concentration (µg/mL)Acknowledgements:Medical writing support was provided by Caroline Spencer and Dr Sue Chambers (Rx Communications, Mold, UK), funded by Fresenius Kabi SwissBioSim.Disclosure of Interests:Christian Schwabe: None declared, Chris Wynne: None declared, Andras Illes Employee of: Fresenius Kabi SwissBioSim, Martin Ullmann Employee of: Fresenius Kabi SwissBioSim, Emmanuelle Vincent Employee of: Fresenius Kabi SwissBioSim, Vishal Ghori Employee of: Fresenius Kabi SwissBioSim, Corinne Petit-Frere Employee of: Biosimilars, Fresenius Kabi SwissBioSim, Anne-Sophie Racault Employee of: Fresenius Kabi SwissBioSim, Isabelle Morin Employee of: Former employee of Fresenius Kabi SwissBioSim
Collapse
|
3
|
Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes. Diabetes Care 2019; 42:192-199. [PMID: 30061316 PMCID: PMC6341285 DOI: 10.2337/dc18-0288] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2018] [Accepted: 06/28/2018] [Indexed: 02/03/2023]
Abstract
OBJECTIVE There are variable reports of risk of concordance for progression to islet autoantibodies and type 1 diabetes in identical twins after one twin is diagnosed. We examined development of positive autoantibodies and type 1 diabetes and the effects of genetic factors and common environment on autoantibody positivity in identical twins, nonidentical twins, and full siblings. RESEARCH DESIGN AND METHODS Subjects from the TrialNet Pathway to Prevention Study (N = 48,026) were screened from 2004 to 2015 for islet autoantibodies (GAD antibody [GADA], insulinoma-associated antigen 2 [IA-2A], and autoantibodies against insulin [IAA]). Of these subjects, 17,226 (157 identical twins, 283 nonidentical twins, and 16,786 full siblings) were followed for autoantibody positivity or type 1 diabetes for a median of 2.1 years. RESULTS At screening, identical twins were more likely to have positive GADA, IA-2A, and IAA than nonidentical twins or full siblings (all P < 0.0001). Younger age, male sex, and genetic factors were significant factors for expression of IA-2A, IAA, one or more positive autoantibodies, and two or more positive autoantibodies (all P ≤ 0.03). Initially autoantibody-positive identical twins had a 69% risk of diabetes by 3 years compared with 1.5% for initially autoantibody-negative identical twins. In nonidentical twins, type 1 diabetes risk by 3 years was 72% for initially multiple autoantibody-positive, 13% for single autoantibody-positive, and 0% for initially autoantibody-negative nonidentical twins. Full siblings had a 3-year type 1 diabetes risk of 47% for multiple autoantibody-positive, 12% for single autoantibody-positive, and 0.5% for initially autoantibody-negative subjects. CONCLUSIONS Risk of type 1 diabetes at 3 years is high for initially multiple and single autoantibody-positive identical twins and multiple autoantibody-positive nonidentical twins. Genetic predisposition, age, and male sex are significant risk factors for development of positive autoantibodies in twins.
Collapse
|
4
|
Abstract P5-20-07: A phase Ib dose-finding study of subcutaneous pertuzumab in combination with subcutaneous trastuzumab in healthy male volunteers and female patients with early breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-20-07] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
A fixed-dose combination (FDC) of subcutaneous (SC) pertuzumab (F. Hoffmann-La Roche Ltd, Basel, Switzerland) + SC trastuzumab (F. Hoffmann-La Roche Ltd) is being developed to reduce the treatment burden on patients while improving treatment facility efficiency. This phase Ib dose-finding study (NCT02738970) aimed to identify the SC pertuzumab dose that is comparable to the intravenous (IV) dose, based on serum trough concentrations (Ctrough) and area under the concentration–time curve (AUC) when administered with or without SC trastuzumab.
Methods:
This two-part study consisted of SC pertuzumab dose determination in healthy male volunteers (HMVs) (Part 1) and a subsequent SC pertuzumab dose confirmation in patients with early breast cancer (EBC) (Part 2). Part 1 of the study was comprised of 48 HMVs who received various SC pertuzumab doses (400–1200 mg) or the standard IV dose (420 mg), administered alone or co-mixed with SC trastuzumab 600 mg. Non-compartmental and statistical methods were used to test the pharmacokinetic (PK) interaction between SC pertuzumab and SC trastuzumab when administered with recombinant human hyaluronidase, a permeation enhancer. Two population PK (popPK) models were built to estimate PK parameters and PK variability. Model 1 used IV/SC PK data from Part 1 of the current study only. Model 2 used Part 1 SC PK data and PK parameters from the published IV pertuzumab popPK model (Garg A, et al. Cancer Chemother Pharmacol 2014; 74: 819–829). Each popPK model was used to simulate 400 phase III clinical trials. Per simulated trial, the geometric mean ratio (GMR) of Cycle 8 Ctrough at steady state and AUC at steady state for SC/IV were calculated. The percentage of trials with the 5th percentile confidence interval of the GMR above 0.8 was tabulated.
Results:
In Part 1 of the study, there was no impact on pertuzumab or trastuzumab PK from co-mixing SC trastuzumab with SC pertuzumab. The absolute bioavailability of SC pertuzumab in HMVs was approximately 70–80%, with a median time to reach maximum concentrations of 4–5 days. Clinical trial simulations indicated that an SC pertuzumab dose of 600 mg will achieve the target Ctrough and AUC SC/IV GMRs > 99% of the time. Results were consistent between the models. Safety data supported the selection of an SC pertuzumab maintenance dose of 600 mg. The 600 mg SC pertuzumab dose determined in HMVs was confirmed in Part 2 of the study in patients with EBC.
Conclusions:
These data support the development of an SC pertuzumab + SC trastuzumab FDC product.
Citation Format: Kirschbrown WP, Wynne C, Kagedal M, Wada R, Li H, Nijem I, Badovinac Crnjevic T, Heeson S, Eng-Wong J, Garg A. A phase Ib dose-finding study of subcutaneous pertuzumab in combination with subcutaneous trastuzumab in healthy male volunteers and female patients with early breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-20-07.
Collapse
|
5
|
Neuroblastoma in a 6-year-old boy. Postgrad Med J 2016; 93:367. [PMID: 27899686 DOI: 10.1136/postgradmedj-2016-134586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Revised: 11/04/2016] [Accepted: 11/05/2016] [Indexed: 11/03/2022]
|
6
|
|
7
|
Bicycle helmet wearing in a sample of urban disadvantaged primary school children. IRISH MEDICAL JOURNAL 2013; 106:102-104. [PMID: 23691841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Bicycle helmet wearing is currently not legally enforced in Ireland and little is known about the self-reported practice amongst young children. The principal aim of this study was to assess self-reported helmet wearing amongst a sample (n = 314) of primary school children (aged 8-13 years) attending disadvantaged schools in Dublin. Approximately 86% of the sample owned a bike and provided a response to the question on helmet use. The findings indicate that helmet wearing is not a widespread practice (50.4%; 136/270 report never wearing helmets). As children get older, reported practice is also less likely with 67% (27/40) of 12/13 year-olds compared to 38% (31/81) of 8/9 year-olds reporting never wearing protective headgear. Regardless of age, more girls (61%; 82/135) than boys (39%; 52/135) indicated always/sometimes using helmets when cycling. Conversely, the findings show that (mandatory) seatbelt wearing is standard practice for the majority (93%; 252/270). The findings relating to helmet wearing add further to the debate around the mandatory introduction of protective headgear for cyclists.
Collapse
|
8
|
496 oral IMPORTANT MORTALITY REDUCTIONS BY SHORT TERM ANDROGEN DEPRIVATION AND RADIOTHERAPY FOR LOCALLY ADVANCED PROSTATE CANCER: 10 YEAR TRIAL DATA FROM TROG 96.01. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70618-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
9
|
A History of Dogs as Subjects in North American Experimental Psychological Research. COMPARATIVE COGNITION & BEHAVIOR REVIEWS 2011. [DOI: 10.3819/ccbr.2011.60001] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
10
|
Radiation myelopathy after 36 Gy in 12 fractions palliative chest radiotherapy for squamous cell cancer of the lung: case report and review of published studies. Clin Oncol (R Coll Radiol) 2010; 22:561-3. [PMID: 20570499 DOI: 10.1016/j.clon.2010.05.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2010] [Revised: 03/31/2010] [Accepted: 04/07/2010] [Indexed: 11/17/2022]
Abstract
A 55 year old man was treated with 36 Gy in 12 fractions palliative chest irradiation for squamous cell carcinoma of the lung. This was followed by 3 cycles of cisplatin and gemcitabine. Five months later he developed clinical and imaging findings consistent with radiation myelopathy. The maximum spinal cord dose was 38.9 Gy. The possible contributions of portal imaging and gemcitabine are discussed and the literature reviewed.
Collapse
|
11
|
Randomised, placebo-controlled, crossover trial of sildenafil citrate in the treatment of erectile dysfunction following external beam radiation treatment of prostate cancer. J Med Imaging Radiat Oncol 2010; 54:224-8. [DOI: 10.1111/j.1754-9485.2010.02168.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Common and Unique Aspects of Impulsivity: The Neural Correlates of Inhibiting Rewards, Responses and Emotions. Neuroimage 2009. [DOI: 10.1016/s1053-8119(09)70765-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
13
|
Suppression of bone resorption from odanacatib, a cathepsin K inhibitor, in women with bone metastases from breast cancer, and the effect of concomitant anti-neoplastic treatment on efficacy: a 4-week, double-blind, randomized controlled trial. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-1157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #1157
Background: In breast cancer patients with metastatic bone disease (MBD), an osteolytic process releases factors that sustain tumor cell survival and proliferation. Cathepsin (Cat) K inhibition suppresses osteolysis in preclinical models of MBD. This study assessed the efficacy and safety of odanacatib, a potent and reversible selective Cat K inhibitor, in reducing markers of bone resorption in women with breast cancer and MBD depending on concomitant anti-neoplastic treatment.
 Materials and Methods: Women with breast cancer and MBD were randomized (double-blind) to oral odanacatib 5 mg daily for 4 weeks or IV zoledronic acid (ZA) 4 mg given once at study initiation. Bone resorption was assessed by urinary N-telopeptide of type I collagen corrected for creatinine (uNTx). A post-hoc analysis of the influence of concomitant therapy (chemotherapy vs hormone therapy) on study medication effects on uNTx was also conducted. Adverse events (AE) were monitored throughout the 4-week study and up to 14 days after last dose.
 Results: 43 patients (mean age 60 yrs) received odanacatib (n=29) or ZA (n=14); 40 patients completed all 4 weeks of treatment. 12 (41%) and 17 (59%) patients on odanacatib and 6 (46%) and 7 (54%) patients on ZA received chemotherapy or hormone therapy, respectively; one patient was on both co-therapies and one patient on ZA was not on concomitant therapy. Results for the effect of study medication on uNTx as well as the effects of concomitant therapy on each treatment group are shown in the table; results for the full analysis set were similar. The most common reported AEs were nausea, vomiting, headache, and bone pain, and generally not attributed to study drug.
 Conclusions: In women with breast cancer and MBD, the Cat K inhibitor, odanacatib, suppressed markers of bone resorption after 4 weeks of treatment. Mean uNTx was decreased in both treatment groups. The effect on biomarkers observed in this study was seen irrespective of concomitant anti-neoplastic treatment. Odanacatib was generally safe and well tolerated. These results suggest that Cat K inhibition is a potentially important, novel therapeutic approach for treating MBD.
 

Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1157.
Collapse
|
14
|
Effect of cathepsin k inhibition on suppression of bone resorption in women with breast cancer and established bone metastases in a 4-week, double-blind, randomized controlled trial. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1023] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Interpreting the improved outcome of patients with central nervous system metastases managed in clinical trials compared with standard hospital practice. AUSTRALASIAN RADIOLOGY 2005; 49:390-5. [PMID: 16174177 DOI: 10.1111/j.1440-1673.2005.01500.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The aims were to determine the median survival and prognostic factors of patients with central nervous system (CNS) metastases managed with whole-brain radiation therapy (WBRT), and to explore selection criteria in recently published clinical trials using aggressive interventions in CNS metastases. A retrospective audit was performed on patients managed with WBRT for CNS metastases. Potential prognostic factors were recorded and analysed for their association with survival duration. The proportion of patients with these factors was also compared with those of patients managed under three recently reported studies investigating aggressive interventions, such as radiosurgery and chemotherapy for CNS metastases. Seventy-three patients were treated with WBRT for cerebral metastases over a 12-month period. The median survival of the population was 3.4 months (95% confidence interval: 2.7-4.1), with 6- and 12-month survival rates of 30 and 18%, respectively. Significant prognostic factors for prolonged median survival were Eastern Cooperative Oncology Group status 0-2 (P = 0.015), Medical Research Council neurological functional status 0-1 (P = 0.006), and Recursive Partitioning Analysis Class 2 versus Class 3 (P = 0.020). On multivariate analysis, younger patient age (P = 0.02) and better performance status (P < 0.01) were associated with improved outcome. When comparing these characteristics with selected published studies, our study cohort demonstrated a higher proportion of patients with poor performance status, a greater number of metastases per patient and a higher incidence of extracranial disease. This reflects the selected nature of patients in these published studies. Central nervous system metastases confer a poor prognosis and, for the majority of patients, aggressive interventions are unlikely to improve survival. The use of potentially toxic and expensive treatments should be reserved for those few in whom these studies have shown a potential benefit.
Collapse
|
16
|
Evaluation of a radiotherapy protocol based on INT0116 for completely resected gastric adenocarcinoma. Int J Radiat Oncol Biol Phys 2003. [DOI: 10.1016/s0360-3016(03)01299-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Abstract
The aim of this study is to assess the content of letters sent from a hospital oncology service regarding the initial assessment of new referrals and the requirements of hospital specialists and General Practitioners (GPs) regarding oncology service correspondence. The content of letters regarding the initial consultation of 204 consecutive new oncology patients was analysed. General Practitioners and referring specialists were sent a 13-point survey to gauge their preferences for the information contained in oncology correspondence pertaining to the initial assessment of an oncology patient. Seventy-two percent of the patients had a letter written following their initial oncology assessment. The GP received a copy of 81% of the letters (58% of the study sample). The diagnosis was recorded in all our letters, and the proposed treatment plan was addressed in 84% of our letters. Both GPs and specialists required information on examination and investigation findings, diagnosis, treatment options, proposed management plan, and what the patient was told. The GPs required further information on current medication, likely side-effects of the proposed management, and clarification of when to contact the oncologist. The majority of the respondents were in favour of a structured letter.
Collapse
|
18
|
The pre-operative identification of low-risk endometrialcancer: an audit of women treated in the South Island of New Zealand 1998-2000. Aust N Z J Obstet Gynaecol 2002; 42:387-90. [PMID: 12403287 DOI: 10.1111/j.0004-8666.2002.00389.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To determine whether pre-operative investigations identify a group of patients with low-risk endometrial cancer, who do not require tertiary referral for surgical staging or pelvic radiotherapy. DESIGN Retrospective chart review. SETTING South Island of New Zealand gynaecological oncology services. SAMPLE One hundred and forty consecutive patients with newly diagnosed endometrial cancer from 1988 to 2000. METHODS The results of preoperative investigations were compared with the final pathology. MAIN OUTCOME MEASURES Correlation of preoperative investigations with low risk disease. For the purpose of the study, women with grade 1 or 2 endometrioid tumours confined to the uterine body and less than 50% myometrial invasion were considered to have low risk disease. RESULTS In total, 50 women had low risk disease. Only 53% of patients with grade 1 tumours on initial biopsy had low risk disease. Women who had a grade 1 tumour at biopsy and, an ultrasound report with an endometrial thickness of less than 20 mm, and no evidence of myometrial invasion, cervical involvement or adnexal metastasis had a 76% chance of having low risk disease. CONCLUSION We were unable to accurately define the low risk group from pre-operative assessment.
Collapse
|
19
|
Detecting adverse drug reactions. CMAJ 1999; 161:247-8. [PMID: 10463044 PMCID: PMC1230497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023] Open
|
20
|
Abstract
This article begins with a discussion of the types of cancer that are most often the target of cancer screening in general medical practice. Colorectal, prostate, cervical, and breast cancer screening guidelines are reviewed and some of the evidence (and controversy) behind these recommendations is discussed. A discussion of some of the special risks for cancer in patients with rheumatologic disease follows, and some modifications of standard screening guidelines are suggested for these high-risk patients.
Collapse
|
21
|
Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group. Ann Oncol 1997; 8:277-83. [PMID: 9137798 DOI: 10.1023/a:1008291825695] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
PURPOSE To investigate the effect of two doses of megestrol acetate (MA) compared with placebo on quality of life (QoL) and nutritional status (NS) in patients with advanced endocrine-insensitive cancer. PATIENTS AND METHODS Two hundred forty patients were randomised to double-blind MA 480 mg/day, MA 160 mg/day, or matching placebo for 12 weeks. Nutritional status (including weight, skinfold thickness and midarm circumference) and QoL (using 6 linear analogue self-assessment (LASA) scales) were assessed at randomisation and after four, eight and 12 weeks. A QoL ranking incorporating QoL and death was also used ranging from 1 = dead to 5 = much better QoL. RESULTS One hundred seventy-four patients were assessable at week four, 136 at week eight and 103 patients at week 12. Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend. A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001). Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002). Improvements in QoL occurred early within four weeks and were sustained. No statistically significant differences were observed in NS measurements, including weight (P = 0.29). Side effects of therapy were minor and did not differ significantly across treatments. CONCLUSION Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer. It improves appetite, mood and overall quality of life in these patients, although not through a direct effect on nutritional status.
Collapse
|
22
|
Abstract
Conformal photon and proton therapy plans for prostate cancer have been compared in an attempt to quantify the potential advantages of using protons. Two X-ray plans (3-field, 6-field) and a 2-field proton plan were made and compared for each of 20 T3 prostate patients with the aid of the 3D planning system VOXELPLAN. Dose distributions were analysed in terms of dose-volume histograms (DVH). Tumour control probability (TCP) and normal tissue complication probability (NTCP) were computed using our own and the Lyman-Kutcher-Burman models, respectively. The study shows that on average the proton technique results in the best dose distribution, giving the lowest rectal complication probability, and also that the 3-field X-ray technique is more effective than the 6-field X-ray technique in sparing the rectum. At 5% rectal NTCP, the predicted proton average TCP for the 20 patients is 2% (in absolute terms) greater than that obtained using 3-field X-ray therapy. For 7 of the patients the gain in TCP is more than 3%. For the same rectal NTCP as the 3-field X-ray plan with a 64 Gy mean target dose, the use of protons increases the TCP by 2% on average, but for 5 of the patients the increases are greater than 4%. The result is in general positive towards the use of protons but a few patients do not benefit from it and this indicates the importance of patient selection for maximum clinical benefit.
Collapse
|
23
|
Controversies in the management of laryngeal cancer: results of an international survey of patterns of care. Radiother Oncol 1994; 31:23-32. [PMID: 8041896 DOI: 10.1016/0167-8140(94)90410-3] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Cancer of the larynx is the most prevalent non-cutaneous malignancy of the head neck region and its treatment presents a threat to both natural speech and survival. This study examines the manner in which two separate specialties in the same and different geographic regions vary in their opinions about the treatment of glottic laryngeal cancer. The goal was to define options available to patients and to classify controversies about optimal treatment which might be resolved in clinical trials. Questionnaires depicting different presentations of glottic larynx cancer were mailed to 1649 otolaryngologists and radiation oncologists in North America, Europe and Australasia. Half the doctors were asked to describe their preferred treatment for a patient while the others were asked to imagine that they themselves were the patient. In all the disease situations opinions varied significantly with respect to the treatment modality advised (whether to employ surgical or radiotherapy approaches) and in more extensive disease situations the intention of treatment also varied depending on whether a curative approach should involve conservation or loss of the larynx. Doctors also recommended similar treatment for their patients as they would for themselves. Apart from disease extent the most significant variables influencing recommendations were the physicians' specialty (P = 0.0001) and where they practice (P = 0.0001). These findings demonstrate diversity of opinion which is influenced more profoundly by the traditions of the specialties and geographic location of practice than by the reported results of treatments for laryngeal cancer. Convictions about optimal management have become barriers to the assessment of the relative value of different treatments and to ensuring that patients are fully informed about management options. The profession should regard as a high priority efforts to resolve these therapeutic conflicts which are associated with major differences in quality of life.
Collapse
|
24
|
Abstract
Conformal radiotherapy seeks to allow increased intensity of radiation by reducing the volume of normal tissues within the treatment volume. Techniques have developed secondary to improvements in three-dimensional imaging and accessible treatment technology is based on computer-controlled multileaf collimators to create an irregular radiation beam shape. Preliminary clinical work in the Royal Marsden Hospital seeks to quantify the toxicity reduction achievable by conformal techniques in the context of a prospective randomized pelvic radiotherapy trial which has now recruited 240 patients. The data accumulated during this trial will allow comparison of conformal and conventional radiotherapy and also analysis of the impact of dose and volume of a particular organ on both acute and late toxicity. Assessments have revealed that conformal techniques reduced significantly the treatment volume of normal tissues, e.g. by a mean of 54% for rectum and 42% for bladder. However, a relationship between volume and acute toxicity has not been established. Late toxicity is currently being analysed. Dose escalation trials in thoracic and in pelvic tumours are planned.
Collapse
|
25
|
Abstract
During the period 1973 to 1982, 35 patients with carcinoma of the anal canal were seen at this hospital. The main form of treatment was abdominoperineal excision, unless specific contraindications to this procedure were present. Between 1982 and 1984, a further 18 such patients were seen; the primary method of treatment then was combination chemotherapy and radiotherapy. Abdominoperineal excision was reserved for those patients who failed to respond to therapy or whose carcinoma recurred during the period of follow-up. The over-all five-year survival rate for the first 35 patients was 50%; the actuarial disease-free survival at two years for those who went into complete remission was 78% in the 18 patients who were seen in the second part of the study. We conclude that conservative treatment by chemoradiation is of value in the management of anal carcinomas.
Collapse
|
26
|
Abstract
Plasma antidiuretic hormone concentrations were measured in a group of children with acute asthma and in a control group. Very high levels of antidiuretic hormone were found in the asthmatic group. There were no changes in other biochemical indices. If overproduction of antidiuretic hormone is sustained then fluid administration to children with severe acute asthma is potentially dangerous.
Collapse
|